Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on T-cell-based immunotherapies targeting infectious diseases and oncology. The company went public through a SPAC merger and filed an S-1/A amendment on July 23, 2024, accession number 0001493152-24-028834, registering shares as part of its post-combination equity structure. Operating in the biotechnology sector, Tevogen Bio has built its pipeline around off-the-shelf T-cell receptor technology designed to generate broad immune responses. The company remains in the clinical development stage with no approved products on the market as of the filing date. For complete filing history, ownership data, and deal-level analytics on TVGN and thousands of other SPAC-linked companies, sign up for full access at SpacDesk.